SG Americas Securities LLC sells Myriad Genetics, Inc. (NASDAQ:MYGN) stock.

During the third quarter, SG Americas Securities LLC sold off 43.4% of its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) shares, as stated in the most recent SEC filing that the company submitted. The company now owns a total of 29,966 of the company’s shares of the stock following the sale of 23,023 shares during the quarter. The value of SG Americas Securities LLC’s holdings in Myriad Genetics was determined to be $572,000 after the most recent reporting period.

A variety of additional hedge funds and institutional investors have also modified the percentage of MYGN that they own as a result of these changes. First Horizon Advisors, Inc.

Increased its holdings in Myriad Genetics during the second quarter by investing approximately $57,000 to purchase additional company stock shares.

Point72 Hong Kong Ltd.

Increased the percentage of ownership it held in Myriad Genetics by 722.8% over the second quarter of the fiscal year.

Point72 Hong Kong Ltd now owns 3,217 shares, valued at $58,000, after purchasing 2,826 additional shares during the most recent period.

During the most recent period, During the second quarter, Exchange Traded Concepts LLC achieved a 216.7% increase in the amount of stock in Myriad Genetics that it owned.

Exchange Traded Concepts LLC now has 3,588 shares of the company’s stock, worth a combined total of $65,000 due to purchasing an additional 2,455 shares during the relevant period.

During the third quarter, The Ronald Blue Trust Inc.

Increased the amount of Myriad Genetics stock it owns by 21.2%, bringing its total ownership percentage to 100%. Following the acquisition of 775 shares during the relevant period, Ronald Blue Trust Inc. now holds 4,439 shares of the company’s stock, with an estimated $81,000.

And finally, during the third quarter, CWM LLC increased its ownership of Myriad Genetics by 17.8% by purchasing additional shares. CWM LLC now has 4,291 shares, valued at $82,000, after purchasing 648 shares during the period in question. The vast majority of the company’s stock is owned by institutional investors and hedge funds, accounting for 99.08% of the total.
The NASDAQ: MYGN stock was listed for trading for the first time on Tuesday for $21.41 per share. The price of a share of Myriad Genetics, Inc. has been as high as $28.18 and as low as that price throughout the year. The stock has traded at an average price of $18.04 per day over the past 50 trading days, while the price has been $20.49 per day on average over the last 200 trading days. The company has a P/E ratio of -22.07, and its beta value is 1.75. The market capitalization of the company is currently sitting at $1.73 billion at the moment.

On November 1, the most recent quarterly financial report for Myriad Genetics, which is traded on the NASDAQ under the symbol MYGN, was made available to the general public. The company’s earnings per share were $0.27, representing a decrease of $0.12 compared to the consensus estimate of $0.15 per share for the company’s quarterly earnings.

In their financial statements, Myriad Genetics revealed a negative net margin of 11.69% and a negative return on equity of 4.86%. The company reported revenue for the quarter of $156.40 million, which is significantly lower than the estimates provided by industry professionals, which were $172.12 million.

According to the projections made by research analysts, earnings for the current fiscal year at Myriad Genetics, Inc.

Are forecasted to come in at a loss of 0.8 cents per share.

In various analyst reports, MyGN has been brought up as a topic of discussion. On October 12, an article was published on StockNews.com that served as the kickoff to the website’s coverage of Myriad Genetics. They recommended that shareholders “hold” their shares of the company.

In a research note published on January 18, Raymond James changed their rating of the company to “outperform” and raised their price target to $25.00.

In addition, they stated that they expect the stock to reach that price. SVB The price objective Leerink has established for Myriad Genetics has been reduced from $27.00 to $25.00, as stated in a research note published on November 2.

In addition, they gave the company a rating of “market perform,” which indicates that they believe the company will continue to trade within the same price range it is currently trading in. With the publication of a research note on the subject of myriad genetics on October 5, Stephens finally made his long-awaited debut as a writer after much anticipation. The company received a rating of “equal weight” from the organization, and the price goal that it was aiming for was set at $22. The stock has been recommended to sell by one of the equity research analysts, a recommendation to hold it by three, and a recommendation to buy by one.

According to Bloomberg, the average recommendation for the company is “Hold,” and the consensus for the price target on the stock is $25.40.

According to earlier reports concerning Myriad Genetics, Chief Financial Officer Richard Bryan Riggsbee sold 20,000 shares of the company’s stock on Tuesday, December 27. This transaction was reported in previous stories about the company. The price paid for each share, on average, was $15.15, which resulted in the sale of a total amount of stock equal to $303,000.00.

After the completion of the sale, the chief financial officer now directly controls 374,107 shares of the company, the total value of which is approximately $5,667,721.50 at the moment. Should you follow this link, you will be taken to the SEC filing in which the transaction was discussed in greater detail.

Insiders in the company have sold 30,000 shares of stock over the most recent three months, realizing a total profit of $503,382 due to their actions.

At this time, corporate insiders hold 1.80% of the company’s shares in their accounts.

Myriad Genetics, Inc.

Is the company that is responsible for the development and marketing of genetic tests, both in the United States and internationally.

Myriad Genetics, Inc markets these tests. The company offers molecular diagnostic assays that can be implemented in oncology, women’s, and mental health settings.

Patients with metastatic breast, ovarian, pancreatic, or prostate cancer who have deleterious or suspected deleterious germline BRCA variants can benefit from the BRACAnalysis CDx Germline Companion Diagnostic Test that this service provides. This test is a DNA sequencing analysis that helps patients.

In addition, it offers the MyRisk Hereditary Cancer Test, a DNA sequencing test that can evaluate a person’s likelihood of developing a form of cancer that runs in their family.

DNA sequencing technology is used in both of these diagnostic procedures.

In addition to this, it offers a tumor marker test that is referred to as the MyChoice CDx Companion Diagnostic Test.

Read more here: Source link